Drugs / ETV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04781647 Background | Feb 2021 → Dec 2022 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04781647 ↗ |
| Route | Oral | “0.5 mg tablets orally once daily” NCT04781647 ↗ |